Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 268

Sort by

Sort Order Select

Journal Articles

BH3 profiling identifies ruxolitinib as a promising partner for venetoclax to treat T-cell prolymphocytic leukemia

Blood (2021) 137 (25): 3495–3506.

https://doi.org/10.1182/blood.2020007303

Published: 2021

Includes: Supplemental data

Journal Articles

Polytypic T-cell prolymphocytic leukemia

Erik Ames, Oscar Silva

Blood (2021) 137 (15): 2125.

https://doi.org/10.1182/blood.2021010694

Published: 2021

Journal Articles

Mechanistic Insights into the Inhibition of T Regulatory Cells By Dasatinib May Predict Immunostimulatory Effects in CML Patients

Patrick Harrington, MRCP, FRCPath, Richard Dillon, MA, PhD MRCP, FRCPath, Philippe Rousselot, MD PhD, Deepti Radia, Yvonne Francis, Claire N Harrison, Professor, Shahram Kordasti, MD PhD, Hugues De Lavallade

Blood (2019) 134 (Supplement_1): 1635.

https://doi.org/10.1182/blood-2019-129135

Published: 2019

Journal Articles

Large Granular Lymphocytosis and Its Impact on Long Term Clinical Outcomes Following Allogeneic Hematopoietic Stem Cell Transplantation: 14-Year Follow-up Data

Guldane Cengiz Seval, Atilla Uslu, MD, Ekin Kircali, Sinem Civriz Bozdag, MD, Klara Dalva, MD, Selami Kocak Toprak, MD, Meltem Kurt Yuksel, MD, Pervin Topcuoglu, MD, Isinsu Kuzu, Onder Arslan, Muhit Özcan, Taner Demirer, MD, Osman Ilhan, MD, Hamdi Akan, MD, Meral Beksac, MD, Gunhan Gurman, MD

Blood (2019) 134 (Supplement_1): 2019.

https://doi.org/10.1182/blood-2019-128750

Published: 2019

Journal Articles

Severe Chronic Neutropenia in the Large Granular Lymphocyte Syndrome: Outcomes in Response to Granulocyte Colony Stimulating Factor (G-CSF) and Immunosuppressive Therapies

David C. Dale, MD, James A. Shannon, IV, Audrey Anna Bolyard, RN, BS, Jim Connelly, MD, Daniel C. Link, MD, Mary Ann Bonilla, MD, Peter E. Newburger, MD

Blood (2019) 134 (Supplement_1): 3589.

https://doi.org/10.1182/blood-2019-126181

Published: 2019

Journal Articles

Novel Drugs and Clinical Trial-Based Treatments Prolong Survival of Peripheral T-Cell Lymphomas (PTCL) Patients: Single Institution Retrospective Analysis

Helen Ma, MD, Enrica Marchi, MD, PhD, Bin Cheng, PhD, Govind Bhagat, MD, Owen A. O'Connor, MD PhD

Blood (2019) 134 (Supplement_1): 3486.

https://doi.org/10.1182/blood-2019-123587

Published: 2019

Journal Articles

No Improvement in Survival for T-PLL Patients over the Last Two Decades

Matthew J Cross, MBBS, BSc, Monica Else, Ricardo Morilla, Mark Edward Ethell, MD, Michael Potter, MD, Dima El-Sharkawi, Sunil Iyengar, MBBS, FRCPath, PhD, Claire E. Dearden, MD FRCP, FRCPath

Blood (2019) 134 (Supplement_1): 1552.

https://doi.org/10.1182/blood-2019-122094

Published: 2019

Journal Articles

STAT3 Mutations and Anemia with Pure Red Cell Aplasia Are the Distinctive Features of T Cell Receptor Gamma Delta Type Large Granular Lymphocyte Leukemia

Taku Yamane, Toru Kawakami, MD, Nodoka Sekiguchi, MD PhD, Jun Kobayashi, Toshimitsu Ueki, MD, Hikaru Kobayashi, MD PhD, Sayaka Nishina, Kaoko Sakai, MD, Hitoshi Sakai, MD, Kazuo Oshimi, MD, Yumiko Higuchi, PhD, Hideyuki Nakazawa, MD PhD, Fumihiro Ishida, MD PhD

Blood (2019) 134 (Supplement_1): 1500.

https://doi.org/10.1182/blood-2019-123614

Published: 2019

Journal Articles

Identification of Novel Therapeutic Targets in Atm-Deficient Lymphomas Using a Whole Genome CRISPR/CAS-9 Screen

Tatjana Stankovic, MD PhD, Nicholas Davies, PhD, Louise J Tee, Andrew D Beggs, Malcolm Taylor, PhD

Blood (2019) 134 (Supplement_1): 1504.

https://doi.org/10.1182/blood-2019-129974

Published: 2019

Journal Articles

Prospective, Multicentric Phase II Randomized Trial Comparing the Efficacy of Methotrexate or Cyclophosphamide in Large Granular Lymphocytic Leukemia: A French National Study. Report on the Interim Analysis

Blood (2019) 134 (Supplement_1): 1545.

https://doi.org/10.1182/blood-2019-123439

Published: 2019

Journal Articles

Incidence of Germline ATM Variants in a Consecutive Clinical Cohort of CLL Patients

Benjamin L. Lampson, MD PhD, Svitlana Tyekucheva, PhD, Conner J. Shaughnessy, Annette S. Kim, MD PhD, Jennifer R. Brown, MD PhD

Blood (2019) 134 (Supplement_1): 1731.

https://doi.org/10.1182/blood-2019-127180

Published: 2019

Journal Articles

Blockade of IL-15 Utilizing Bnz-1, a Selective γ-Chain Inhibiting Peptide, Is Safe and Has Clinical Activity in Patients with T-Cell Large Granular Lymphocytic Leukemia (T-LGLL): Results of a Phase I/II Multi-Center Clinical Trial

Jonathan E. Brammer, MD, Lubomir Sokol, MD PhD, Yutaka Tagaya, MD PhD, Kerry Rogers, Anjali Mishra, PhD, Thomas A. Waldmann, MD, Nazli Azimi, PhD PharmD, Paul Frohna, MD PhD PharmD, Anoshie Ratnayake, MD, Thomas P Loughran, Jr., MD, Karen Ballen, MD

Blood (2019) 134 (Supplement_1): 2835.

https://doi.org/10.1182/blood-2019-129291

Published: 2019

Journal Articles

Long-Term Experience with Large Granular Lymphocytic Leukemia Evolving after Solid Organ and Hematopoietic Stem Cell Transplantation

Hassan Awada, Reda Z. Mahfouz, MD PhD, Jibran Durrani, Ashwin Kishtagari, MBBS, Deepa Jagadeesh, MDMPH, Alan Lichtin, MD, Brian T. Hill, MD, Betty K. Hamilton, MD, Hetty E. Carraway, MD MBA, Navneet S. Majhail, MD MS, Ronald Sobecks, MD, Valeria Visconte, PhD, Matt Kalaycio, MD, Mikkael A. Sekeres, MD MS, Jaroslaw P. Maciejewski, MD PhD

Blood (2019) 134 (Supplement_1): 1226.

https://doi.org/10.1182/blood-2019-130167

Published: 2019

Journal Articles

Congenital STAT3 mutation Mediates Primary Persistent Polymorphic Inflammatory Activation and T Cell Leukemogenesis

Hongxing Liu

Blood (2019) 134 (Supplement_1): 1054.

https://doi.org/10.1182/blood-2019-132138

Published: 2019

Journal Articles

Characterizing the Anti-Apoptotic Dependencies of T-Cell Prolymphocytic Leukemia Identifies HDAC and JAK/STAT Pathway Inhibitors As Promising Combination Partners to Augment Bcl-2 Targeted Killing By Venetoclax

Blood (2019) 134 (Supplement_1): 807.

https://doi.org/10.1182/blood-2019-126773

Published: 2019

Journal Articles

Final Results of a Phase II Biomarker-Driven Study of Ruxolitinib in Relapsed and Refractory T-Cell Lymphoma

Blood (2019) 134 (Supplement_1): 4019.

https://doi.org/10.1182/blood-2019-125017

Published: 2019

Journal Articles

Pembrolizumab and Copanlisib for the Treatment of Relapsed or Refractory Mature T-Cell Lymphomas

Stefan K. Barta, MD MRCP, MS, Nathan H. Fowler, MD, Jasmine Zain, MD, Jia Ruan, MD PhD, Sonali M. Smith, MD, Stephen J. Schuster, MD, Sunita D Nasta, MD, Jakub Svoboda, MD, James N Gerson, MD, Daniel J. Landsburg, MD, Elise A. Chong, MD, Henry C. Fung, FRCP,MBBChir, Kerry S Campbell, PhD, Nadia Khan, MD, Richard I. Fisher, MD, Carlyn Rose Tan, MD

Blood (2019) 134 (Supplement_1): 4031.

https://doi.org/10.1182/blood-2019-125385

Published: 2019

Journal Articles

Reversible DNA Hypermethylation of the Interleukin-15 (IL-15) Promoter Induces IL-15 Expression, Drives the Pathogenesis of T-Cell Large Granular Lymphocytic Leukemia and Provides a Potential Therapeutic Approach Using 5-Azacitidine

Jonathan E Brammer, MD, Amy E Boles, BS, Anthony Mansour, MD, Aharon G. Freud, MD PhD, Monique Mathé-Allainmat, Agnès Quéméner, Erwan Mortier, Pierluigi Porcu, MD, Anjali Mishra, PhD

Blood (2019) 134 (Supplement_1): 3776.

https://doi.org/10.1182/blood-2019-131174

Published: 2019

Journal Articles

Aberrant SYK Expression As a Potential Therapeutic Target in T/NK Cell Neoplasms

Jing-Ping Zhang, PhD, Qi Gao, MLS, Alexander Chan, MD, Wenbin Xiao, MD PhD, Sary El Daker, PhD, Mikhail Roshal, MD PhD, Ahmet Dogan, MD PhD

Blood (2019) 134 (Supplement_1): 3978.

https://doi.org/10.1182/blood-2019-130406

Published: 2019

Journal Articles

Combination of Venetoclax and Ibrutinib Increases bcl2-Dependent Apoptotic Priming, Reduces ITK-Phosphorylation and Is Clinically Promising in Relapsed/Refractory T-Prolymphocytic Leukemia

Christoph Kornauth, Charles Herbaux, MD MSc, Bernd Boidol, PhD, Chantal Guillemette, Patrick Caron, Stéphanie Poulain, MD PhD, Olivier Tournilhac, Marius E Mayerhoefer, Ulrich Jaeger, MD, Stefan Kubicek, Matthew S. Davids, MD, Philipp Bernhard Staber, MD PhD

Blood (2019) 134 (Supplement_1): 3965.

https://doi.org/10.1182/blood-2019-124392

Published: 2019

NARROW

BH3 profiling identifies ruxolitinib as a promising partner for venetoclax to treat T-cell prolymphocytic leukemia

Polytypic T-cell prolymphocytic leukemia

Mechanistic Insights into the Inhibition of T Regulatory Cells By Dasatinib May Predict Immunostimulatory Effects in CML Patients

Large Granular Lymphocytosis and Its Impact on Long Term Clinical Outcomes Following Allogeneic Hematopoietic Stem Cell Transplantation: 14-Year Follow-up Data

Severe Chronic Neutropenia in the Large Granular Lymphocyte Syndrome: Outcomes in Response to Granulocyte Colony Stimulating Factor (G-CSF) and Immunosuppressive Therapies

Novel Drugs and Clinical Trial-Based Treatments Prolong Survival of Peripheral T-Cell Lymphomas (PTCL) Patients: Single Institution Retrospective Analysis

No Improvement in Survival for T-PLL Patients over the Last Two Decades

STAT3 Mutations and Anemia with Pure Red Cell Aplasia Are the Distinctive Features of T Cell Receptor Gamma Delta Type Large Granular Lymphocyte Leukemia

Identification of Novel Therapeutic Targets in Atm-Deficient Lymphomas Using a Whole Genome CRISPR/CAS-9 Screen

Prospective, Multicentric Phase II Randomized Trial Comparing the Efficacy of Methotrexate or Cyclophosphamide in Large Granular Lymphocytic Leukemia: A French National Study. Report on the Interim Analysis

Incidence of Germline ATM Variants in a Consecutive Clinical Cohort of CLL Patients

Blockade of IL-15 Utilizing Bnz-1, a Selective γ-Chain Inhibiting Peptide, Is Safe and Has Clinical Activity in Patients with T-Cell Large Granular Lymphocytic Leukemia (T-LGLL): Results of a Phase I/II Multi-Center Clinical Trial

Long-Term Experience with Large Granular Lymphocytic Leukemia Evolving after Solid Organ and Hematopoietic Stem Cell Transplantation

Congenital STAT3 mutation Mediates Primary Persistent Polymorphic Inflammatory Activation and T Cell Leukemogenesis

Characterizing the Anti-Apoptotic Dependencies of T-Cell Prolymphocytic Leukemia Identifies HDAC and JAK/STAT Pathway Inhibitors As Promising Combination Partners to Augment Bcl-2 Targeted Killing By Venetoclax

Final Results of a Phase II Biomarker-Driven Study of Ruxolitinib in Relapsed and Refractory T-Cell Lymphoma

Pembrolizumab and Copanlisib for the Treatment of Relapsed or Refractory Mature T-Cell Lymphomas

Reversible DNA Hypermethylation of the Interleukin-15 (IL-15) Promoter Induces IL-15 Expression, Drives the Pathogenesis of T-Cell Large Granular Lymphocytic Leukemia and Provides a Potential Therapeutic Approach Using 5-Azacitidine

Aberrant SYK Expression As a Potential Therapeutic Target in T/NK Cell Neoplasms

Combination of Venetoclax and Ibrutinib Increases bcl2-Dependent Apoptotic Priming, Reduces ITK-Phosphorylation and Is Clinically Promising in Relapsed/Refractory T-Prolymphocytic Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only